Is resistin a link between highly active antiretroviral therapy and fat redistribution in HIV-infected children?

Journal of Endocrinological Investigation

Volumn 31, Issue 7, 2008, Pages 592-596

  Spagnuolo, M I ^a   Bruzzese, E ^a   Vallone, G F ^a   Fasano, N ^a   De Marco, G ^a   Officioso, A ^a   Valerio, G ^b   Volpicelli, M ^a   Iorio, R ^a   Franzese, A ^a   Guarino, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

Children; Fat redistribution; HAART; HIV; Lipodystrophy; Resistin; Visceral fat

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; PROTEINASE INHIBITOR; RESISTIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE THICKNESS; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT DISTRIBUTION; BODY FAT REDISTRIBUTION; CENTRAL LIPOHYPERTROPHY; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPOATROPHY; LIPOHYPERTROPHY; METABOLIC DISORDER; MONOTHERAPY; PROTEIN BLOOD LEVEL; RESISTIN SERUM LEVEL; SERUM RESISTIN BLOOD LEVEL; SIDE EFFECT; SUBCUTANEOUS FAT; THICKNESS; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASOUND;

EID: 54949130164     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345607     Document Type: Article

References (35)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353: 2093-9.
2. Mc Dermott AY, Shevitz A, Knox T, Roubenoff R, Kehayas J, Gorbach S. Effect of highly active antiretroviral therapy on fat, lean, bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001, 74: 679-86.
3. Bochkorst JL, Ksseriy I, Toye M, et al. Evidence of human immunodeficiency virus associated lipodystrophy syndrome in children with protease inhibitors Pediatr Infect Dis J 2003, 22: 463-5.
4. Nolan D, Mallal S. Antiretroviral-therapy-associated lipoatrophy: current status and future directions Sex Health 2005, 2: 153-63.
5. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy Antivir Ther 2003, 8: 9-15.
6. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000, 11: 327-32.
7. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004, 89: 200-6.
8. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15: F11-8.
9. Estrada V, Serrano-Rios M, Martinez Larrad MT, et al. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 29: 32-40.
10. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998, 280: 1843-8.
11. Vigano A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003, 32: 482-9.
12. Graber AL. Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection. Endocr Pract 2001, 7: 430-7.
13. Pontiroli AE, Pizzocri P, Giacomelli M, et al. Ultrasound measurement of visceral and subcutaneous fat in morbidly obese patients before and after laparoscopic adjustable gastric banding: comparison with computerized tomography and with anthropometric measurements. Obes Surg 2002, 12: 648-51.
14. Armellini F, Zamboni M, Harris T, Micciolo R, Bosello O. Sagittal diameter minus subcutaneous thickness. An easy-to-obtain parameter that improves visceral fat prediction. Obes Res 1997, 5: 315-20.
15. Zamboni M, Turcato E, Armellini F, et al. Sagittal abdominal diameter as a practical predictor of visceral fat. Int J Obes Relat Metab Disord 1998, 22: 655-60.
16. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000, 25: 312-21.
17. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004, 255: 439-47.
18. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized controlled trial. Ann Intern Med 2004, 140: 786-94.
19. Barb D, Wadhwa SG, Kratzsch J, et al. Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome. J Clin Endocrinol Metab 2005, 90: 5324-8.
20. Kamin D, Hadigan C, Lehrke M, Mazza S, Lazar MA, Grinspoon S. Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. J Clin Endocrinol Metab 2005, 90: 3423-6.
21. Youn BS, Yu KY, Park HJ, et al. Plasma resistin concentrations measured by ELISA using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004, 89: 150-6.
22. Fujinami A, Obayashi H, Ohta K, et al. Enzymelinked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 2004, 339: 57-63.
23. Volarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004, 53: 1279-84.
24. Lee JH, Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88: 4848-56.
25. Moon B, Kwan JJ, Duddy N, Sweeney G, Begum N. Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 2003, 285: E106-15.
26. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-β selectively impair insulin action on glucose production. J Clin Invest 2003, 111: 225-30.
27. Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003, 300: 674-8.
28. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor - action in humans. Diabetes 2001, 50: 2199-202.
29. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger - RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003, 309: 286-90.
30. Patel L, Buckels AC, Kinghom IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR activators. Biochem Biophys Res Commun 2003, 300: 472-6.
31. Cacciari E, Milani S, Balsamo A, Dammacco F, De Luca F, Chiarelli F. Italian cross-sectional growth charts for height, weight and BMI (6-20 y). Eur J Clin Nutr 2002, 56: 171-80.
32. European Paediatric Lipopdystrophy Group. Anteretroviral therapy, fat redistribution and hyperlipidemia in HIV-infected children in Europe. AIDS 2004, 18: 1443-51.
33. Snijder MB, Visser M, Dekker JM, et al. The prediction of visceral fat by dual-energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry. Int J Obes Relat Metab Disord 2002, 26: 984-93.
34. Hickman TB, Briefel RR, Carroll MD, et al. Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey. Prev Med 1998, 27: 879-90.
35. Laron Z, Huerter P, Weber B. Standardization of oral glucose tolerance test. Acta Paediatr Belg 1977, 30: 124-5.